Novavax (NVAX)
(Delayed Data from NSDQ)
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Zacks News
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $22.81, marking a +1.02% move from the previous day.
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Company News for Oct 21, 2022
by Zacks Equity Research
Companies in The News Are: TSLA, T, ABB, MRNA, NVAX
Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab
by Zacks Equity Research
Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
by Zacks Equity Research
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) Reports Positive Data on COVID/FLU Combo Jab Study
by Zacks Equity Research
Novavax (NVAX) reports positive data from its phase I/II study evaluating a combination of its COVID-19 and the seasonal influenza vaccine.
Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland
by Zacks Equity Research
The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.
Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?
by Zacks Equity Research
Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $18.20, moving -1.99% from the previous trading session.
Why Novavax (NVAX) Stock Was Down 13% on Thursday
by Zacks Equity Research
Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.
Vaccine Stocks Down After Biden Says Pandemic is Over
by Kinjel Shah
BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
by Zacks Equity Research
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax (NVAX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $32.55, making no change from the previous trading session.
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults
by Zacks Equity Research
Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.
Novavax (NVAX) Down 29.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland
by Zacks Equity Research
Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.
Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation
by Zacks Equity Research
The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.
PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion
by Ekta Bagri
Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.